Santiago Jiménez-Marrero, Miguel Cainzos-Achirica, David Monterde, Emili Vela, Cristina Enjuanes, Sergi Yun, Alberto Garay, Pedro Moliner, Miriam Corbella, Sílvia Jovells-Vaqué, Lídia Alcoberro, Alexandra Pons-Riverola, Raul Ramos-Polo, Herminio Morillas, Joan Antoni Gómez-Hospital, Josep Comin-Colet
BACKGROUND: Renin-angiotensin-aldosterone system inhibitors (RAASIs) play a crucial role in the treatment of several chronic cardiovascular conditions. Nonetheless, hyperkalemia, a frequent side effect, often leads to the discontinuation of RAASIs. The implications of hyperkalemia-driven changes in RAASI medications are poorly understood. METHODS: Population-based, observational, retrospective cohort study. Two large healthcare databases were utilized to identify 77,089 individuals aged 55 years and older with chronic conditions who were prescribed RAASIs between 2015 and 2017 in Southern Barcelona, Spain...
March 27, 2024: European Journal of Internal Medicine